MYL : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  3. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  4. Dr. Reddy's Launches Generic Dacogen - Analyst Blog

    July 15, 2013
    Dr. Reddy's announced the launch of its therapeutic equivalent generic version of Astex/ Eisai's Dacogen.
  5. FDA Approves Actavis Generic - Analyst Blog

    July 15, 2013
    Actavis is yet to fix its launch plans for the newly approved dosage strengths.
  6. Stock Market News for July 15, 2013 - Market News

    July 15, 2013
    Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
  7. FTC Request for ACT-WCRX Deal - Analyst Blog

    July 12, 2013
    The companies still expect the acquisition to close in the second half of 2013.
  8. Mylan Notches Patent Court Fight Win - Analyst Blog

    July 9, 2013
    Mylan received a favorable verdict in a patent infringement case with Sunovion.
  9. Estarylla Lot Recalled by Novartis' Sandoz - Analyst Blog

    July 8, 2013
    Sandoz recently announced that it is voluntarily recalling one lot of its oral contraceptive drug, Estarylla (norgestimate ...
  10. Perrigo Attains 52- week High - Analyst Blog

    July 8, 2013
    Shares of Perrigo Company soared to a 52-week high of $123.95 on Jul 5.
  11. Mylan Inks Deal - Analyst Blog

    July 1, 2013
    Mylan Inc. signed a distribution agreement with Zyomyx.
  12. Label Expansion for Astellas Drug - Analyst Blog

    June 17, 2013
    Astellas Pharma Inc. announced the approval of Prograf in Japan for an additional indication
  13. $2.15B Settlement for Pfizer's Protonix - Analyst Blog

    June 13, 2013
    While Teva will make a payment of $1.6 billion, Sun Pharma will pay the remaining $550 million.
  14. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  15. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  16. Dr. Reddy's Misses on Both Counts - Analyst Blog

    February 15, 2013
    Dr. Reddy's Laboratories (RDY) reported third quarter fiscal 2013 earnings per American Depositary Share (ADS) of 40 cents, ...
  17. Perrigo in Expansion Mode - Analyst Blog

    February 12, 2013
    Perrigo Company (PRGO) recently announced that it is set to acquire a UK-based privately held pharmaceutical company, Rosemont ...
  18. Supernus' Update on Oxtellar - Analyst Blog

    February 8, 2013
    Supernus Pharmaceuticals, Inc. (SUPN) recently provided information on its agreement with Patheon Inc. (PNHNF) for the manufacture, ...
  19. Actavis Provides 2013 Guidance - Analyst Blog

    January 31, 2013
    Actavis, Inc. (ACT), formerly known as Watson Pharmaceuticals, Inc., recently provided an update on its 2012 performance, ...
  20. Santarus Files Suit against Mylan - Analyst Blog

    January 30, 2013
    Santarus, Inc. (SNTS) recently filed a patent infringement lawsuit against Mylan, Inc. (MYL) which is looking to launch a ...
  21. Earnings Preview: Merck - Analyst Blog

    January 30, 2013
    Merck & Co. Inc. (MRK) is scheduled to report its fourth quarter 2012 results on Feb 1, 2013 before the opening bell. Last ...
  22. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  23. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  24. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  25. Earnings Preview: Perrigo Company - Analyst Blog

    January 29, 2013
    We expect  Perrigo Company (PRGO) to beat expectations when it releases its second quarter fiscal 2013 results before the ...
  26. Launches Continue at Perrigo - Analyst Blog

    January 24, 2013
    Perrigo Company (PRGO) recently announced that it has launched over-the-counter (OTC) nicotine polacrilex mini lozenge, 2 ...
  27. Perrigo Launches Generic Luxiq Foam - Analyst Blog

    January 16, 2013
    Perrigo Company (PRGO) recently announced that it has launched betamethasone valerate foam 0.12%.  It is the generic equivalent ...
  28. Another Generic Launch at Mylan - Analyst Blog

    December 31, 2012
    Mylan Inc. (MYL) recently announced that it has launched its generic version of Teva's (TEVA) Nordette 28 Tablets (levonorgestrel ...
  29. Stock Market News for December 20, 2012 - Market News

    December 20, 2012
    Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into the ...
  30. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  31. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  32. Stock Market News for November 13, 2012 - Market News

    November 13, 2012
    Apprehension about this week's "fiscal cliff" discussion between top U.S. leaders and President Barack Obama led to benchmarks ...
  33. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  34. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  35. Stock Market News for October 17, 2012 - Market News

    October 17, 2012
    Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks into the ...
  36. Mylan in Neutral Lane - Analyst Blog

    October 10, 2012
    We are maintaining our Neutral recommendation on Mylan Inc. (MYL) with a target price of $26.00. The stock carries a Zacks ...
  37. Shire Aims to Expand Vyvanse Label - Analyst Blog

    September 17, 2012
    Shire plc (SHPG) recently announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental ...
  38. Dr. Reddy's Launches Generic Toprol - Analyst Blog

    September 12, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
  39. Dr. Reddy's Expands Portfolio - Analyst Blog

    August 9, 2012
    Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) blockbuster asthma ...
  40. Another Copaxone Win for Teva - Analyst Blog

    July 12, 2012
    Teva Pharmaceutical Industries Ltd. (TEVA) recently announced another favorable decision regarding its Copaxone patent. The ...
  41. Bristol-Myers Shares Positive Data - Analyst Blog

    June 11, 2012
    Recently, Bristol-Myers Squibb (BMY) and partner AstraZeneca (AZN) presented encouraging data from a phase III study (n=447) ...
  42. Obama’s Corporate Tax Proposal: Which Companies Will Take A Hit?

    February 24, 2012
    President Obama has proposed corporate tax cuts that will lower corporate income taxes from 35% to 28%, but claims he willl ...
  43. Teva And Mylan Show Some Value Remains In Generics

    August 4, 2011
    These two generics companies seem to be heading in opposite directions, but the values are similar.
  44. Tepid Teva Somewhat Tempting

    February 9, 2011
    Teva's results and outlook will likely leave the stock cooling its heels for a bit in this growth-obsessed market, but patient ...
  45. Profit From Teva's Travails

    July 29, 2010
    Wall Street is giving investors the chance to purchase a top-tier generics company at a discount price.
  46. Convertible Securities On The Right Track

    September 11, 2009
    For those who need income but don’t want to miss out on moves in the overall market.
  47. J&J Looks To Get Back On Track

    July 15, 2009
    Investors are waiting for J&J to return to its heyday of double-digit growth.
  48. Chico's Tops Companies With Insider Buying

    April 21, 2009
    When a company is trading near its high and has recent insider buying, it's definitely worth a closer look.
  49. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  50. Heavy Volume Movers For October 9

    October 9, 2008
    Find tomorrow's winners today by following high-volume stocks. We track five of the market's top movers of the day.
  51. Meet Teva, The Generic Giant

    May 15, 2008
    Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals has all ...
  52. Barr Poised To Run (BRL)

    September 26, 2007
    Billions of dollars in brand name drugs are set to lose patent protection, and Barr pharmaceuticals is ready to take advantage.
  53. Mulling Mid-Cap Medicine (SEPR, MYL, KG)

    July 9, 2007
    A look at three mid-cap pharmaceutical companies with three very different approaches to business.
  54. Pfizer's Down, But Not Out (PFE)

    January 24, 2007
    While Pfizer's current issues are cause for concern, the company's long-term plans make it worth a second look.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center